NEXAVAR |
SORAFENIB |
BAY-43-9006 |
N-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)-N'-(4-(2-(N-METHYLCARBAMOYL)-4-PYRIDYLOXY)PHENYL)UREA |
SORAFENIBUM |
NEXAVAR® |
4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-METHYL-2-PYRIDINECARBOXAMIDE |
BAY 43-9006 |
chemidplus:284461-73-0 |
pubchem.compound:216239 |
chembl:CHEMBL1336 |
drugbank:00398 |
rxcui:495881 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Year of Approval | 2005 |
FDA Approval | Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma |
Drug Class | Kinase Inhibitors |
inhibitor (inhibitory) |
Trial Name | Nexavar |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Novel drug target | Established target |
Trial Name | Nexavar |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Variant Effect | gain-of-function |
Pathway | activation |
Clinical Status | case report |
inhibitor (inhibitory) |
Trial Name | Nexavar |
Novel drug target | Established target |
Clinical Status | preclinical |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Evidence Type | Actionable |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Indication/Tumor Type | thyroid medullary carcinoma |
Response Type | predicted – sensitive |
Approval Status | Phase II |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Nexavar |
Novel drug target | Established target |
Notes |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Nexavar |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
n/a |
combination therapy | Cisplatin + Gemcitabine + Sorafenib |
Indication/Tumor Type | invasive bladder transitional cell carcinoma |
Response Type | predicted – resistant |
SORAFENIB | Generic Name |
NEXAVAR | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma |
SORAFENIB | Primary Drug Name |
Year of Approval | 2005 |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
CHEMBL1336 | ChEMBL Drug ID |
D0W5HK | TTD Drug ID |
SORAFENIB | Primary Drug Name |
SORAFENIB | Drug Generic Name |
NEXAVAR | Drug Trade Name |